Introduction
Dendritic Cells (DCs) are specialized phagocytic cells that are influential in the control of the innate and adaptive immune responses (1) . Circulating through most tissues, DCs possess qualities that allow them to rapidly recognize foreign from self-entities, efficiently intercept and process material, and then display antigen in the context of the major histocompatibility complex (MHC) to the T-cell receptor on T-cells (1, 2) . While much attention has been paid to the role of DCs as strong, "natural adjuvants" (3) , their function in the initiation of suppressive networks required for maintenance of peripheral tolerance is more recently being uncovered (4) .
Moreover, effecting dendritic cells with regulatory functions, or "tolerogenic DCs" (tDCs) is emerging as an immunotherapeutic goal (5) .
Of particular interest is the application of tDCs for the abrogation of autoimmune diseases and transplant rejection. Tolerogenic dendritic cells initiate a number of modalities that can lead to hyporesponsiveness by effector immune cells. These include anergic pathways, regulatory T cell generation (Treg), as well as effector T-cell deletion (1) . So far, therapeutic approaches have primarily entailed the use of exogenously manipulated DCs conditioned with tolerance-inducing factors (e.g. oligonucleotides, corticosteroids, cytokines) to produce tDCs that are re-introduced to the body (6) (7) (8) . A number of pharmacological and biological agents have been investigated to generate tDCs. For instance, studies have shown that administration of either biological agents like the cytokines, interleukin-10 (IL-10) and transforming growth factor beta-1 (TGF-β1), or pharmacological drugs such as rapamycin (RAPA), and all-trans retinoic acid (RA) have been explored for this application (9-13).
Interleukin-10 is a pleiotropic immunomodulatory cytokine expressed and secreted by helper T cells and antigen presenting cells (APCs) (14) . This immuno-suppressive cytokine initiates its effects via binding the extracellular region of the transmembrane IL-10 receptor protein (14) . IL-10-treated DCs show reduced cytokine production (including IL-1, IL-10 itself, IL-12, TNF), and reduced MHCII and co-stimulatory molecule (e.g. CD80, 86) which correlated with the ability of these DCs to inhibit activation when coupled with allogeneic T cells (15, 16) .
Another pleiotropic, anti-inflammatory cytokine of interest is TGF-β1. Transforming growth factor is produced and secreted in a latent form by an array of lymphoid cells, particularly DCs and T cells, and can exhibit paracrine effects via binding cell surface membrane-bound receptors (17, 18) . These cells are not only sources for TGF-β1 but also targets of action for this immunosuppressive cytokine. The scope of impact of TGF-β1 on DCs is still being discovered, but it has been demonstrated TGF-β1 immuno-modulatory effects are inhibitory in nature and lead to a tolerogenic DC phenotype that is capable of inducing antigen-specific CD25 + FoxP3 + T cells (induced Tregs) from CD + 4 naïve T cell population (19, 20) . Notably, TGF-β1-conditioned DCs produce indoleamine 2,3 deoxgenase (IDO), an enzyme involved in tryptophan catabolism and responsible for the generation of kynurenines. Kynurenines are thought to be a key factor in the spread of 'infectious tolerance', a state where tolerance is thought to be spread from one immune cell population to another (21) .
The pharmacologic drug, rapamycin (RAPA) is a macrolide antibiotic derived from the filamentous bacterium, Streptomyces hygroscopicus (22) . Rapamycin exerts potent immunosuppressive action, via binding the intracellular membrane-bound mammalian target of rapamycin (mTOR) complex (22) , on immune cells including T cells and DCs. In DCs, rapamycin has been implicated for inhibition of cytokine-mediated signal transduction. It has been demonstrated that exposure of DCs to RAPA results in reduced expression of MHCII and co-stimulatory molecules, LPS resistance as well as inability to stimulate allogenic T cells in vitro (23) . In vivo, it has been suggested that RAPA-treated DCs are capable of generating CD4 + CD25 + FoxP3 regulatory T cells in addition to inducing apoptosis of effector T cells resulting in transplant acceptance in various mouse models (23, 24) . Lastly, all-trans retinoic acid (RA), a metabolite of vitamin A, is the final immunosuppressive agent presently considered.
All-trans retinoic acid can act through the nuclear receptor, retinoic acid receptor, to modulate both innate and adaptive immune cellular elements (25, 26) . In APCs, RA treatment results in diminished production of inflammatory cytokines such as IFN-γ (27, 28) . Further, supplementation of vitamin A and its metabolites in mice have been reported to mitigate autoimmune diseases including type 1 diabetes and encephalomyelitis (29) (30) (31) ).
An emerging theme is that co-administration of immunomodulatory agents can produce cumulative, sometimes synergistic effects on DC populations that boost robust immune modulation. For example, RA acts a co-factor to TGF-β1 on CD103 + DCs derived from gut associated lymphatic tissue, enhancing their ability to generate FoxP3 + Tregs (32) . In this work, we explore combinatorial co-delivery of these factors in a targeted, localized controlled release manner, achieved through polymeric microparticulate delivery systems. We hypothesize such multi-factor particulate systems could benefit autoimmune and transplant applications, offering reduced doses and yielding immunoregulatory effects not achievable by delivering a single factor. Targeted, local, controlled delivery of these factors can be accomplished through poly (lactic-co-glycolic acid) (PLGA) microparticles (MPs).
Poly (lactic-co-glycolic acid) particulate systems have been widely established as a delivery system for a plethora of biomolecules, and pharmacological agents (33) (34) (35) (36) (37) . Key qualities include biocompatibility, biodegradability and tunable release kinetics. Additionally, PLGA MPs can be fabricated to specific micron size ranges, which is a key consideration for phagocytic cell targeting (34, 37 
Materials and Methods

Microparticle Preparation
A 50:50 polymer composition of poly(d,l-lactide-co-glycolide) (PLGA) (MW ~ 44,000 g/mol) in methylene chloride (MC) (Purac) was used to generate MPs. Polyvinyl alcohol (PVA; 87% hydrolyzed) (MW ~ 100,000 g/mol) was purchased from Fisher Scientific (NJ, USA) and was used as an emulsion stabilizer. Distilled water (DiH 2 O) was used as the aqueous phase to form the emulsions while methylene chloride (Fisher Scientific, NJ, USA) was used as the organic solvent to dissolve the PLGA polymer. Microparticles were formed using a standard oilwater solvent evaporation technique.
To make phagocytosable MPs, 100 mg of PLGA polymer was dissolved in methylene chloride at 5% w/v ratio. Either Rapamycin (RAPA) (LC Laboratories) or All-trans Retinoic acid (RA) (Acros Organics) in DMSO was loaded into 2 ml of 5% PLGA solution. This solution was added to 2 ml of 5% PVA solution in DiH 2 O and homogenized at 35,000 rpm for 180 s using a tissue-miser homogenizer (Fisher Scientific, NJ, USA) to form a primary emulsion. This was added to 30 ml of 1% PVA solution. The particles thus formed were agitated using a magnetic stirrer (Fisher Scientific, NJ, USA) for 24 h to evaporate residual methylene chloride.
The remaining solution was centrifuged at 10,000 x g for 10 min to collect MPs which were subsequently washed three times with DiH 2 O. The water was aspirated from the centrifuged MPs, which were then flash-frozen in liquid nitrogen and kept under vacuum in dry ice overnight. The MPs were stored at -20 o C until used. Unphagocytosable MPs (TGF-β1-and IL-10-loaded) (BD Pharmingen) were fabricated using by a double emulsion solvent evaporation technique similar to that described above but with the addition of a second emulsification step and using a vortexter (Fisher Scientific) instead of a homogenizer. The TGF-β1 solution was reconstituted in 10mM Citric Acid and 2 mg/ml bovine serum albumin in PBS to a final concentration of 100 µg/ml. For IL-10, after a quick spin the lyophilized powder was reconstituted in DiH 2 O to a concentration of 100 µg/ml.
2.2
Microparticle Characterization -Sizing, Loading, Release Kinetics
The size distribution of the MP was measured by the Microtrac Nanotrac Dynamic Light Scattering Particle Analyser (Microtrac, Montgomery, PA). Particle sizes are reported as the average diameter ± standard deviation (S.D.).
The loading efficiency of the phagocytosable MPs was measured by dissolving 100 mg of MPs into 2 ml MC and re-precipitating the PLGA with a known volume of methanol (Acros Organics). The suspension was centrifuged and the supernatant removed to a new tube.
Following evaporation, residue remaining in the tube is concentrated in a known, small quantity of DMSO and the solution concentration measured by spectrophotometer. For the second particle type (unphagocytosable), loading efficiency was measured using a solvent evaporation technique followed by spectrophotometric analysis.
The in vitro release kinetics from MPs was determined as described. Briefly, a known Unloaded MPs and the soluble equivalent of released drugs doses (RAPA -30 ng/ml; RA -22 ng/ml; TGF-β1 -11 ng/ml; IL-10 -5 ng/ml) were included as controls. 
Statistical Analysis
Statistical analyses were performed using general linear model ANOVA, followed by posthoc assessment using Tukey test to make pair-wise comparisons. Differences were considered significant when p ≤ 0.05 using Systat (Version 12, Systat Software, Inc., San Jose, CA).
Results
Microparticle characterization
Microparticles were fabricated using a single emulsion, solvent evaporation technique for Encapsulation efficiencies for RAPA and RA in MPs were 72 ± 3% and 62 ± 6%, respectively.
The loading efficiencies for MPs prepared by the double emulsion technique, TGF-β1 and IL-10
MPs, were slightly lower at 61 ± 5% and 52 ± 5%, respectively. These loading values are consistent with values reported in previous studies. For instance, Lu et al reported an entrapment efficiency of 84% for TGF-β1 in PLGA MPs using a double emulsion solvent evaporation technique (40) . Similarly, IL-2(similar in mass to IL-10)-loaded MPs had a loading efficiency up to 60% in a study by Thomas et al (41) . Differences in encapsulation efficiencies reflect differences in encapsulate properties, differences in MP preparation techniques between phagocytosable and unphagocytosable MPs, and also differences in initial loading concentrations and solution composition.
The in vitro release kinetics for each MP was examined at pH 7.4 in a 2% Tween20-PBS solution. The release profiles generally provided an initial burst release within the first week followed by a more gradual release for the following three weeks. Differences in release profiles reflect differences in encapsulate properties, and differences in MP preparation methods. For example, the release profile of IL-10 MPs is more linear compared to TGF-β1 MPs. In this case, while the MPs were fabricated similarly by a double emulsion-solvent evaporation process, and the encapsulated proteins only slightly differ in molecular weights, solubility and isoelectric points, the initial loading solutions were different. The TGF-β1was loaded with the excipients -citric acid and bovine serum albumin in a phosphate buffered solution, whereas the IL-10 was reconstituted in only DiH 2 O. Additionally, the drug loading of IL-10 by weight percentage is less than that for TGF-β1 MP loading. Rothstein et al. reported that excipient addition and manipulation of drug loading may modify the "initial burst" typical observed in release of hydrophilic biologicals from PLGA particulate systems (42) . Excipient addition may influence osmotic pressure during fabrication resulting in increased burst magnitude. Initial burst magnitude of MP protein release could also be intensified by an increase of the protein initial loading concentration (42) . We postulate that these factors are influential in the notably different release profiles observed for TGF-β1 MPs and IL-10 MPs. Further, the acidity of microenvironments in the TGF-β1 MP likely accelerates the degradation rate of the polymer and therefore, the initial release burst.
Maturation status of MP-treated DCs
To assess the immunosuppressive ability of the combinatorial multi-factor dual MP systems, we investigated their effects on DC maturation. Specifically, expression of the markers Figure 5A-D) . Notably, the phagocytosable single factor MPs, RAPA MPs and RA MPs, drove the maturation resistance effect, indicating their ability to counteract external maturation stimuli.
Comparing the Sol LPS and Unloaded MPs + Sol LPS groups, reveals the surprising ability of unloaded MPs to confer resistance to maturation, indicating that 50:50 PLGA itself can have biological, immunosuppressive function.
Expression of Ilt3 on DCs exposed to MP formulations
In addition to down-regulating stimulatory markers, one mechanism tDCs can resist activation is through surface expression of inhibitory molecules such as immunoglobulin-like transcript 3 (Ilt3), and high expression of Ilt3 can be a feature of some regulatory DCs (43, 44) .
However, none of the treatments investigated here, either in soluble or MP form, increased Ilt3 expression compared to iDC (Supplement, Figure S3 ). In contrast, the Sol LPS control increased Ilt3 expression to a small extent. In fact, RAPA and RA treatments decreased Ilt3 levels below iDC, and this result with rapamycin is consistent with others (45, 46) . The only MP formulation that maintained Ilt3 levels was the IL-10 MP treatment, which is not inconsistent with other reports that IL-10 exposure induces upregulation of Ilt4, a closely related inhibitory receptor (47, 48).
Suppression of allogenic T-cell proliferation by MP-treated DCs
To determine the suppressive effect of MP-treated DCs (from C57Bl6 mice) on allogenic DCs. However, no additive effect was produced for this combination ( Figure 6B) . The RA/ TGF-β1 dual MP system inhibited T cell proliferation to levels well below either the iDC and Unloaded MPs groups, and to a lower proliferation level than the TGF-β1 MP, but equivalent to the RA MP formulation ( Figure 6C) . Finally, the dual RA/ IL-10 MPs inhibited T cell proliferation to the lowest levels across the combination formulations, well below either the iDC or Unloaded MPs groups ( Figure 6D) . This was the only MP combination which suppressed T cell proliferation to levels significantly lower than both of its single factor MPs. Lastly, a word regarding control groups -without allogeneic DC stimulus, T cell proliferation is minimal as shown in the T cell only group. More interestingly, it is noted that DCs treated with unloaded
MPs have a significant effect on allogeneic T cell proliferation, consistent with the prior result above showing the ability of 50:50 PLGA MPs to confer DC resistance to maturation stimulus.
Generation of Tregs by MP-treated DCs
After determining the highly suppressive nature of our dual MP-treated DCs, we investigated if MP-treated DCs could increase CD4 + CD25 + FoxP3 + regulatory T cell numbers.
The same experimental setup as the above mixed lymphocyte reaction was used and cells were (52, 57) . At a weight loading of 0.18%, it was expected that our rapamycin-loaded MPs would induce responses similar to these studies. In a different study,
Jhunjhunwala et al. fabricated TGF-β1
MPs using an analogous method to that described above.
However, their 25% loading efficiency (53) was much lower than our 61%, an inconsistency which can be accounted for in differences in the composition of loading solutions. In our MP formulations, the release of agents followed general solute release behavior as described by
Fick's second law of diffusion (58) . The general profile follows an initial burst release within the first week followed by steady incremental emission. Release kinetics of our fabricated MPs varied across MP formulation, these profiles could be manipulated through modification of parameters such as polymer molecular weight, lactide to glycolide ratio as well as particle size (37) .
Tolerogenic DCs are typically characterized by reduced levels of expression of stimulatory/costimulatory molecules (e.g., MHC II, CD40, CD80, CD86) and expression of inhibitory markers (e.g., Ilt3) (44) . For this reason, we determined the expression levels of CD80, CD86 and MHC II on DCs exposed to our combination MPs. Salient points to be highlighted from this analysis -(i) all formulations including the unloaded MP group at least maintained an iDC maturation profile, (ii) MPs with encapsulated agents generally effected greater modulation than their soluble equivalent controls and, (iii) combination of single factor MPs does not always lead to cumulative dampening of DC activation markers. These results suggest that microparticles fabricated with 50:50 PLGA are well suited for non-activating applications (39) , that targeted, localized release of factors can be more effective than a soluble dose (59) , and also that various factor combinations should be explored to optimize for DC function, for example, via high throughput platforms (33, 60) . 
68)
Given that we observe low constitutive expression of activation molecules due to dual MP and single MP treatment, it is plausible to attribute suppression to T cell anergy. However, the levels of suppression do not always correlate well with the maturation status for our treatments. 
Conclusion
The ability of combinatorial pairings of immunosuppressive factor-loaded MPs to modulate DC function was examined. Table 1 . Size and encapsulation efficiency of MPs loaded with pharmacological and biological agents.
IL-10 MP Release Profile
Time ( . Pair-wise significant differences from iDC and Unloaded MP groups are denoted by the * symbol (p≤0.05). Briefly, MPs were incubated with C57Bl6 DCs for 2 d followed by washing to remove unbound MPs. Subsequently, freshly-isolated Balbc CD4+ T cells were added to culture wells and co-cultured in a mixed lymphocyte reaction. Allogeneic T cell proliferation was then measured. Data shown represent the mean ± standard error (n ≥ 5). Pair-wise significant differences are denoted by: the * symbol for comparisons to the iDC group; the ** symbol for comparisons to the iDC and Unloaded MPs groups; the £ symbol for comparisons to the iDC, Unloaded MPs and either one of the single factor groups; the ¥ symbol for comparisons to the iDC, Unloaded MPs and both of the single factor groups; and the € symbol for comparisons to the all other groups (p≤0.05).
Figure 7.
Dendritic cells treated with dual MP systems do not produce IFN-γ or IL-4, Th1/Th2 skewing cytokines, but do induce anti-inflammatory cytokine TGF-β1 secretion in a mixed lymphocyte setting. Briefly, MPs were incubated with C57Bl6 DCs for 2 d followed by washing to remove unbound MPs. Subsequently, freshly-isolated Balbc CD4+ T cells were added to culture wells and co-cultured in a mixed lymphocyte reaction (MLR). Following the MLR, supernatants were collected and analyzed for (A) IFN-γ, (B) IL-4, and (C) TGF-β1 cytokines by ELISA. Data shown represent mean cytokine concentration ± standard error (n ≥ 7). Pair-wise significant differences are denoted by: the * symbol for comparisons to the iDC group and the ** symbol for comparisons to the iDC and Unloaded MPs groups (p≤0.05). 
